Surrozen, Inc.
SRZNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSurrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. With a market capitalization of $445.8M, it sits in small-cap territory. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Market Cap
$445.8M
Beta
0.47
P/E (TTM)
—
P/E (Fwd)
-6.09
EPS (TTM)
$-39.08
EPS (Fwd)
$-4.19
ROE
—
ROA
-25.4%
Cash
$102.0M
Total Debt
$6.3M
Free CF
-$21.8M
52W Change
82.9%
Annual Financials
Cash vs Debt
Where SRZN stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, SRZN finished 0.59% below its 150-day moving average ($25.22) and 1.37% above its 200-day moving average ($24.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SRZN overbought or oversold?
At the October 16, 2026 close, SRZN's RSI(14) was 39.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Surrozen, Inc. holds $102.0M in cash against $6.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$21.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
SRZN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SRZN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.